MRO Magazine

Medicrea: 2016 Financial Calendar


January 15, 2016
By Business Wire News

LYON, France & NEW YORK

Regulatory News:

The MEDICREA Group (Paris:ALMED) (Alternext Paris: FR0004178572 – ALMED), which specializes in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, announces its financial calendar for the year ending December 31st 2016. Publications will be submitted after market. This calendar is provided for information only and may be subject to change.

— 2015 Annual results       April, 6th 2016
and 2016 First Quarter sales
— Annual General Meeting June, 7th 2016
— 2016 Half Year sales July, 7th 2016
— 2016 Half Year results September, 8th 2016
— 2016 Third Quarter sales October, 8th 2016
— 2016 Annual sales January, 12th 2017

ABOUT MEDICREA (www.medicrea.com)

The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

MEDICREA has also become a pioneer and global leader in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod) and lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) that are made to measure by a 3D printer.

The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.

MEDICREA is listed on ALTERNEXT Paris
ISIN: FR 0004178572 – Ticker: ALMED

MEDICREA
Denys Sournac, Tel: +33 (0)4 72 01 87 87
Chairman and Chief Executive Officer
dsournac@medicrea.com
or
Fabrice Kilfiger, Tel: +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@medicrea.com
or
NewCap
Financial Communication / Press and Investor Relations
Tristan Roquet Montégon, Tel: +33 (0)1 44 71 94 91
medicrea@newcap.fr